Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Hoth Therapeutics ( (HOTH) ).
On April 22, 2026, Hoth Therapeutics, Inc. filed Articles of Incorporation in Nevada to create Rocket One Inc., a wholly owned subsidiary. The new entity is designed to acquire, own and operate assets in the space industry, with a particular focus on nano rocket systems used to deploy nanosatellites.
The move signals a notable diversification of Hoth Therapeutics’ operations into the commercial space and nanosatellite ecosystem. This strategic step could broaden the company’s business profile and expose shareholders to growth opportunities in the rapidly evolving small-satellite launch and space-technology market.
More about Hoth Therapeutics
Hoth Therapeutics, Inc. is a biopharmaceutical company that develops therapeutic products, though it is now also expanding into adjacent technology sectors. Through new structures such as wholly owned subsidiaries, the company is positioning itself to participate in emerging niche markets beyond its core drug development activities.
Average Trading Volume: 2,703,373
Technical Sentiment Signal: Sell
Current Market Cap: $13.56M
For an in-depth examination of HOTH stock, go to TipRanks’ Overview page.